Načítá se...
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II–III clinical trials evaluating the addition of the...
Uloženo v:
| Vydáno v: | NPJ Breast Cancer |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6715721/ https://ncbi.nlm.nih.gov/pubmed/31482107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-019-0121-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|